Preferred Label : Imlifidase;
UNII : UVJ7NL8S2P;
CAS number : 1947415-68-0;
NCI Metathesaurus CUI : CL1365547;
Origin ID : C170061;
UMLS CUI : C5139878;
Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
https://ansm.sante.fr/tableau-acces-derogatoire/idefirix
2025
false
false
false
France
French
infusions, intravenous
imlifidase
Imlifidase
kidney transplantation
Anti-HLA hyperimmunization
drug information
---
https://www.has-sante.fr/jcms/p_3415679/fr/idefirix-imlifidase-transplantation-renale
2024
false
false
false
France
Hyperimmune state (finding)
Deimmunization
insurance, health, reimbursement
treatment outcome
Awaiting transplantation of kidney (situation)
imlifidase
infusions, intravenous
evaluation of the transparency committee
Imlifidase
---
https://www.has-sante.fr/jcms/p_3318987/fr/idefirix-imlifidase
https://www.has-sante.fr/jcms/p_3319007/fr/decision-n-2022-0059/dc/sem-du-10-fevrier-2022-du-college-de-la-haute-autorite-de-sante-portant-delegation-en-matiere-d-autorisation-d-acces-precoce-idefirix
https://www.has-sante.fr/jcms/p_3319018/fr/decision-n-2022-0086/dc/sem-du-23-fevrier-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-idefirix
2022
false
false
false
France
insurance, health, reimbursement
Imlifidase
desensitization, immunologic
Anti-HLA hyperimmunization
adult
kidney transplantation
HLA antigens
Mac-1-like protein, streptococcus
Mac-1-like protein, streptococcus pyogenes M1 GAS
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3332338/fr/idefirix-imlifidase
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Imlifidase
infusions, intravenous
imlifidase
adult
graft rejection
kidney transplantation
Anti-HLA hyperimmunization
evaluation of the transparency committee
---
https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
imlifidase
orphan drug production
graft rejection
infusions, intravenous
adult
kidney transplantation
product surveillance, postmarketing
histocompatibility
aged
drug interactions
pregnancy
breast feeding
cysteine proteases
cysteine proteases
drug evaluation, preclinical
Imlifidase
Imlifidase
---
